Peter Jenner

39.5k total citations · 7 hit papers
463 papers, 31.0k citations indexed

About

Peter Jenner is a scholar working on Cellular and Molecular Neuroscience, Neurology and Molecular Biology. According to data from OpenAlex, Peter Jenner has authored 463 papers receiving a total of 31.0k indexed citations (citations by other indexed papers that have themselves been cited), including 258 papers in Cellular and Molecular Neuroscience, 253 papers in Neurology and 132 papers in Molecular Biology. Recurrent topics in Peter Jenner's work include Parkinson's Disease Mechanisms and Treatments (230 papers), Neuroscience and Neuropharmacology Research (166 papers) and Neurological disorders and treatments (115 papers). Peter Jenner is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (230 papers), Neuroscience and Neuropharmacology Research (166 papers) and Neurological disorders and treatments (115 papers). Peter Jenner collaborates with scholars based in United Kingdom, United States and Switzerland. Peter Jenner's co-authors include C. D. Marsden, Anthony H.V. Schapira, David T. Dexter, К. Ray Chaudhuri, Barry Halliwell, Sarah Rose, Andrew J. Lees, Jonathan M. Cooper, Bernard Testa and J. B. Clark and has published in prestigious journals such as Nature, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Peter Jenner

460 papers receiving 30.1k citations

Hit Papers

Mitochondrial Complex I Deficiency in Parkinson's Disease 1990 2026 2002 2014 1990 2017 1994 1991 1997 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Mitochondrial Complex I Deficiency in Parkinson's Disease
    1990 1.8k citations Anthony H.V. Schapira, David T. Dexter et al. Journal of Neurochemistry profile →
  2. Non-motor features of Parkinson disease
    2017 1.4k citations Anthony H.V. Schapira, К. Ray Chaudhuri et al. Nature reviews. Neuroscience profile →
  3. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia
    1994 940 citations David T. Dexter, Peter Jenner et al. Annals of Neurology profile →
  4. ALTERATIONS IN THE LEVELS OF IRON, FERRITIN AND OTHER TRACE METALS IN PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES AFFECTING THE BASAL GANGLIA
    1991 858 citations David T. Dexter, Peter Jenner et al. profile →
  5. Oxidative DNA Damage in the Parkinsonian Brain: An Apparent Selective Increase in 8‐Hydroxyguanine Levels in Substantia Nigra
    1997 667 citations C. D. Marsden, Peter Jenner et al. Journal of Neurochemistry profile →
  6. Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease
    1990 564 citations Anthony H.V. Schapira, David T. Dexter et al. Journal of Neurochemistry profile →
  7. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease
    2011 554 citations Susan Duty, Peter Jenner British Journal of Pharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Jenner United Kingdom 81 15.2k 12.5k 9.3k 4.2k 3.3k 463 31.0k
Étienne C. Hirsch France 89 16.2k 1.1× 15.1k 1.2× 9.2k 1.0× 4.6k 1.1× 7.2k 2.2× 311 31.8k
Urban Ungerstedt Sweden 97 9.0k 0.6× 21.9k 1.8× 10.5k 1.1× 4.6k 1.1× 1.9k 0.6× 401 36.5k
J. Timothy Greenamyre United States 83 11.2k 0.7× 13.2k 1.1× 11.4k 1.2× 4.1k 1.0× 3.4k 1.0× 208 25.6k
C. Warren Olanow United States 94 26.9k 1.8× 15.7k 1.3× 9.2k 1.0× 5.5k 1.3× 4.7k 1.4× 303 40.6k
Peter Riederer Germany 91 11.0k 0.7× 12.2k 1.0× 9.8k 1.1× 7.6k 1.8× 6.0k 1.8× 534 35.4k
Anthony H.V. Schapira United Kingdom 104 21.8k 1.4× 12.8k 1.0× 17.5k 1.9× 9.1k 2.2× 4.5k 1.4× 480 43.1k
Serge Przedborski United States 110 21.8k 1.4× 15.3k 1.2× 14.3k 1.5× 7.8k 1.9× 8.4k 2.5× 261 41.6k
Moussa B. H. Youdim Israel 102 12.4k 0.8× 10.2k 0.8× 10.0k 1.1× 7.6k 1.8× 5.0k 1.5× 553 37.1k
M. Flint Beal United States 105 11.7k 0.8× 15.1k 1.2× 19.9k 2.1× 7.8k 1.9× 4.2k 1.3× 273 36.4k
Toshiharu Nagatsu Japan 73 6.6k 0.4× 10.8k 0.9× 9.1k 1.0× 4.0k 0.9× 3.9k 1.2× 612 24.8k

Countries citing papers authored by Peter Jenner

Since Specialization
Citations

This map shows the geographic impact of Peter Jenner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Jenner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Jenner more than expected).

Fields of papers citing papers by Peter Jenner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Jenner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Jenner. The network helps show where Peter Jenner may publish in the future.

Co-authorship network of co-authors of Peter Jenner

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Jenner. A scholar is included among the top collaborators of Peter Jenner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Jenner. Peter Jenner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yegla, Brittney, et al.. (2025). Apomorphine differentially engages the cAMP and β-arrestin signaling pathways relative to dopamine at human dopamine receptors. Journal of Neural Transmission. 132(11). 1751–1760.
2.
Jenner, Peter & Dag Nyholm. (2025). COMT inhibition with entacapone for patients with Parkinson’s disease and motor complications: the novelty of continuous infusion. Journal of Neural Transmission. 133(2). 361–375.
3.
Jenner, Peter, Cristian Falup‐Pecurariu, Valentina Leta, et al.. (2023). Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson’s disease. Journal of Neural Transmission. 130(11). 1337–1347. 3 indexed citations
4.
Schapira, Anthony H.V., К. Ray Chaudhuri, & Peter Jenner. (2017). Non-motor features of Parkinson disease. Nature reviews. Neuroscience. 18(7). 435–450. 1414 indexed citations breakdown →
5.
Modo, Michel, William R. Crum, Anthony C. Vernon, et al.. (2017). Magnetic resonance imaging and tensor-based morphometry in the MPTP non-human primate model of Parkinson’s disease. PLoS ONE. 12(7). e0180733–e0180733. 13 indexed citations
6.
7.
8.
Iravani, Mahmoud M. & Peter Jenner. (2011). Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. Journal of Neural Transmission. 118(12). 1661–1690. 64 indexed citations
9.
10.
Johnston, Tom H., Peter Jenner, & Susan Duty. (2001). Alterations in GABA(B)1B and GABA(B)1C receptor gene expression in the basal ganglia and thalamus of rats bearing A nigrostriatal tract lesion. British Journal of Pharmacology. 133. 1 indexed citations
11.
Pearce, Rachel, et al.. (2001). L -Dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations. Psychopharmacology. 156(4). 402–409. 75 indexed citations
12.
Smith, Lance A., et al.. (2000). Transdermal Administration of Piribedil Reverses MPTP-induced Motor Deficits in the Common Marmoset. Clinical Neuropharmacology. 23(3). 133–142. 28 indexed citations
13.
Johnston, Tom H., Peter Jenner, & Susan Duty. (2000). Changes in GABAB1A and GABAB2 receptor gene expression in the basal ganglia and thalamus of rats with a nigrostriatal tract lesion. British Journal of Pharmacology. 131. 1 indexed citations
14.
Clow, Angela, et al.. (1999). Effect of long-term administration of pergolide and (-) -deprenyl on age related decline in Hole Board activity and antioxidant activity in rats. WestminsterResearch (University of Westminster). 5 indexed citations
15.
Smith, Lance A., Ariel Gordin, Peter Jenner, & C. D. Marsden. (1997). Entacapone enhances levodopa‐induced reversal of motor disability in MPTP‐treated common marmosets. Movement Disorders. 12(6). 935–945. 40 indexed citations
16.
Rose, Sarah, M. Steiger, Mohit Bhatt, et al.. (1994). Plasma HVA Levels Following Debrisoquine Administration Do Not Reflect Cerebral Dopamine Loss in Early Parkinsonʼs Disease. Clinical Neuropharmacology. 17(3). 260–269. 1 indexed citations
17.
Dexter, David T., Peter Jenner, Anthony H.V. Schapira, & C. D. Marsden. (1992). Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. Annals of Neurology. 32(S1). S94–S100. 245 indexed citations
18.
Jenner, Peter. (1987). Progress in Brain Research Volume 65.).. Journal of Neurology Neurosurgery & Psychiatry. 50(6). 826–826. 2 indexed citations
19.
Jenner, Peter. (1987). Benzodiazepine/GABA Receptors and Chloride Channels: Structural and Functional Properties.. Journal of Neurology Neurosurgery & Psychiatry. 50(5). 655–656. 335 indexed citations
20.
Elliott, Peter, et al.. (1976). Substituted benzamides as dopamine antagonists. British Journal of Pharmacology. 57(3). 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Étienne C. Hirsch Breakdown of academic impact, for papers by Urban Ungerstedt Breakdown of academic impact, for papers by J. Timothy Greenamyre Breakdown of academic impact, for papers by C. Warren Olanow Breakdown of academic impact, for papers by Peter Riederer Breakdown of academic impact, for papers by Anthony H.V. Schapira Breakdown of academic impact, for papers by Serge Przedborski Breakdown of academic impact, for papers by Moussa B. H. Youdim Breakdown of academic impact, for papers by M. Flint Beal Breakdown of academic impact, for papers by Toshiharu Nagatsu
Rankless by CCL
2026